Details for New Drug Application (NDA): 022410
✉ Email this page to a colleague
The generic ingredient in SUBOXONE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 022410
Tradename: | SUBOXONE |
Applicant: | Indivior |
Ingredient: | buprenorphine hydrochloride; naloxone hydrochloride |
Patents: | 4 |
Pharmacology for NDA: 022410
Mechanism of Action | Opioid Antagonists Partial Opioid Agonists |
Suppliers and Packaging for NDA: 022410
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410 | NDA | INDIVIOR INC. | 12496-1202 | 12496-1202-3 | 30 POUCH in 1 CARTON (12496-1202-3) / 1 FILM, SOLUBLE in 1 POUCH (12496-1202-1) |
SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410 | NDA | INDIVIOR INC. | 12496-1204 | 12496-1204-3 | 30 POUCH in 1 CARTON (12496-1204-3) / 1 FILM, SOLUBLE in 1 POUCH (12496-1204-1) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FILM;BUCCAL, SUBLINGUAL | Strength | EQ 2MG BASE;EQ 0.5MG BASE | ||||
Approval Date: | Aug 30, 2010 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 7, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATING OPIOID USE DISORDER | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Mar 26, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 3, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION |
Expired US Patents for NDA 022410
Complete Access Available with Subscription